Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology

This article will review the utility for biomarker use throughout the cancer care continuum.Recent FindingsA recent meta-analysis shows utility for troponin in monitoring patients at risk for CTRC during cancer therapy. The role for natriuretic peptides is less clear but may be useful in patients receiving proteasome inhibitors. Early studies explore use of myeloperoxidase, growth differentiation factor 15, galectin 3, micro-RNA, and others as novel biomarkers in CTRC.SummaryBiomarkers have potential to identify subclinical CTRC and may reveal opportunities for early intervention. Further research is needed to elucidate optimal biomarkers and surveillance strategies.
Source: Current Cardiology Reports - Category: Cardiology Source Type: research